A number of other equities analysts have also issued reports on the stock. Credit Suisse Group reiterated a neutral rating on shares of Reckitt Benckiser in a research report on Tuesday, February 20th. Zacks Investment Research upgraded shares of Reckitt Benckiser from a strong sell rating to a hold rating in a research report on Wednesday, December 20th. JPMorgan Chase & Co. reiterated a buy rating on shares of Reckitt Benckiser in a research report on Monday, December 18th. Finally, Societe Generale upgraded shares of Reckitt Benckiser from a hold rating to a buy rating in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $21.00.
Reckitt Benckiser (OTCMKTS:RBGLY) opened at $16.83 on Friday. Reckitt Benckiser has a 12-month low of $15.80 and a 12-month high of $21.79. The company has a debt-to-equity ratio of 1.94, a quick ratio of 0.67 and a current ratio of 0.86.
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl, and Strepsils brand names.
Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.